Startups
Developer of novel pharmaceuticals to treat cancer and metabolic diseases (merged with MabVax Therapeutics)
Overview
Location
United States
Total raised
$6.55M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Nov 20, 2012 | Series B round | $5.25M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 23, 2017 | MabVax Raises $1.3M, Hires Investment Banker To Sell Company | San Diego-based MabVax Therapeutics, a biotechnology developer developing antibody-based treatments for cancer, said on Tuesday that it has raised $1.3M in a Series J Convertible Preferred Stock financing, and has engaged an investment bank... |
| Aug 23, 2017 | Amid dwindling cash and a Nasdaq warning, MabVax seeks ‘strategic options’ | San Diego cancer biotech MabVax Therapeutics is hiring an investment bank to help it find a buyer or sell off its assets as it continues to struggle for cash. The antibody biotech, worth just 51 cents a share this morning, has also been hit... |
| Aug 14, 2017 | MabVax Therapeutics Raises $1.3M In PIPE | San Diego-based biotechnology developer MabVax Therapeutics, which is publicly traded on the Nasdaq as MBVX, said today that it has launched a registered direct offering which will provide the company of $1,312,500. The Series J Convertible... |
| May 22, 2017 | MabVax Therapeutics Raises $4.1M In PIPE | San Diego-based MabVax Therapeutics has raised $4.1M in a Series G funding round, the company announced this morning, in a public offering of common stock and Series G Preferred stock. The company said that OPKO Health and its CEO and Chair... |
| Aug 22, 2016 | MabVax Raises $9.4M In PIPE | San Diego-based oncology drug developer MabVax Therapeutics says it has raised $9.4M in a funding, in a combination of a public offering of its common stock and Series F preferred stock and warrants. The publicly traded company, listed on t... |
| Jul 10, 2014 | MabVax Raises $3M, Completes Merger With Telik | San Diego-based MabVax Therpauetics, a privately held firm which is developing vaccine and antibody therapies for treating cancer, said it has raised $3M in a financing round, and also completed a merger with oncology drug developer Telik. ... |
| Sep 25, 2013 | MabVax Awarded $1.75 Million NIH Grant | San Diego-based MabVax Therapeutics Inc., a small private biotechnology company developing vaccine-based treatments for cancer, has been awarded $1.75 million from the National Institutes of Health. The NIH grant is part of its Small Busine... |
| Nov 20, 2012 | MabVax Therapeutics Closes $5.25M Series B | SAN DIEGO, CA, Privately held clinical stage biotechnology company announced the closing of the first tranche in their Series B financing. >> Click here for more funding data on MabVax Therapeutics >> To export MabVax Therap... |
| Nov 20, 2012 | MabVax Raises $5.25M | San Diego-based MabVax Therapeutics, a developer of immunotherapies aimed at preventing recurrent cancer, said today that it has raised $5.25M in a funding round. The round was led by Numoda Capital Innovation, and also included Burrill Cap... |
Show more
Reviews 0
FAQ about Telik
How much funding has Telik raised?
Telik has raised $6.55M in total across 2 funding rounds.
What funding rounds has Telik raised?
Parsers VC lists 2 funding rounds of Telik, among them a Series B round of $5.25M on Nov 20, 2012.
What has the press written about Telik?
Parsers VC has collected 14 articles mentioning Telik, among them “MabVax Raises $1.3M, Hires Investment Banker To Sell Company” (Aug 23, 2017) and “Amid dwindling cash and a Nasdaq warning, MabVax seeks ‘strategic options’” (Aug 23, 2017).
Is Telik still active?
Yes, Telik is active; its latest activity on Parsers VC dates from Aug 23, 2017.